News

Heralding an evolution of the blood pressure monitoring experience, heart health leader OMRON Healthcare today introduced home blood pressure monitors

Stryker, a global leader in medical technologies, announced that its OptaBlate basivertebral nerve ablation system (OptaBlate BVN) received 510(k) clearance from the U.S. Food and Drug Administration. OptaBlate BVNA is used in a targeted minimally invasive procedure providing long-lasting? vertebrogenic pain relief1.

Gradient Denervation Technologies announced today that its pulmonary denervation system has received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA).

Cortechs.ai, a global leader in AI-driven neuroimaging solutions, today announced a strategic collaboration with the Alzheimer's Network for Treatment and Diagnostics (ALZ-NET) to enhance the quality of care

Elucent Medical (?Elucent?), a leading innovator in the field of guided surgical technologies, announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation for the EnVisio X1? In-Body Spatial Intelligence? System.

Pantai Hospital Kuala Lumpur (PHKL) recently hosted its first-ever Ortho Experience Day, offering a rare, hands-on look at the hospital's cutting-edge MAKO Robotic Surgery System?a transformative tool in joint replacement procedures.

International medical imaging IT and cybersecurity company Sectra (STO: SECT B) announces that Guelph General Hospital in Canada will be the first in the country to add Sectra's digital pathology module

Subtle Medical, a global leader in AI-powered medical imaging enhancement, today announced that SubtleHD? has received Health Canada approval, officially expanding access to its cutting-edge MRI image

Apyx Medical Corporation the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion?, is pleased to announce it has received 510(k) clearance from the U.S. Food and Drug Administration

Roche?announced today it plans to invest up to $550 million in its Diagnostics site in Indianapolis by 2030. The site will become a major hub for the manufacturing of Roche's continuous glucose monitoring (CGM) systems ? marking a new milestone in Roche's long history of revolutionizing healthcare across the globe.